Email this page: News Release

OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial

To (email address):   Separate multiple addresses with commas. Maximum 200 characters.
Your name:
Your email address:   Copy yourself These email addresses will be used to email the page on your behalf and will not be used by OncoGenex Pharmaceuticals, Inc. for any marketing purposes.
Add a comment:
Send:    Full page    Link to page
Type in number:
This helps OncoGenex Pharmaceuticals, Inc. prevent automated submissions.